Anti-cancer effects of curcumin on head and neck cancers

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 9, 2012, Pages 1110-1116

  Gao, Wei ^a   Chan, Jimmy Yu Wai ^a   Wei, William Ignance ^a   Wong, Thian Sze ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Chemotherapeutic agent; Curcumin; Epigenetics regulation; Head and neck cancer

Indexed keywords

CARBOPLATIN; CCAAT ENHANCER BINDING PROTEIN; CETUXIMAB; CISPLATIN; CURCUMIN; CYCLIN DEPENDENT KINASE; DOCETAXEL; FLUOROURACIL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; MATRIX METALLOPROTEINASE; PACLITAXEL; PROTEIN BCL 2; STAT3 PROTEIN;

ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CANCER INVASION; CELL MIGRATION; CELL PROLIFERATION; HEAD AND NECK CANCER; HUMAN; METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); SIGNAL TRANSDUCTION; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CURCUMIN; HEAD; HEAD AND NECK NEOPLASMS; HUMANS; NECK; SIGNAL TRANSDUCTION;

EID: 84872224518     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012803529736     Document Type: Article

References (92)

1. Argiris, A.; Eng, C. Epidemiology, staging, and screening of head and neck cancer. Cancer. Treat. Res., 2003, 114, 15-60.
2. Parkin, D.M.; Bray, F.; Ferlay, J.; Pisani, P. Global cancer statistics, 2002. CA. Cancer. J. Clin., 2005, 55, 74-108.
3. D'Souza, G.; Kreimer, A.R.; Viscidi, R.; Pawlita, M.; Fakhry, C.; Koch, W.M.; Westra, W.H.; Gillison, M.L. Case-control study of human papillomavirus and oropharyngeal cancer. N. Engl. J. Med., 2007, 356, 1944-1956.
4. Marur, S.; Forastiere, A.A. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo. Clin. Proc., 2008, 83, 489-501.
5. Argiris, A.; Karamouzis, M.V.; Raben, D.; Ferris, R.L. Head and neck cancer. Lancet, 2008, 371, 1695-1709.
6. Wong, S.J.; Harari, P.M.; Garden, A.S.; Schwartz, M.; Bellm, L.; Chen, A.; Curran, W.J.; Murphy, B.A.; Ang, K.K. Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): analysis of chemoradiation treatment approaches in the United States. Cancer, 2011, 117, 1679-1686.
7. Vermorken, J.B.; Mesia, R.; Rivera, F.; Remenar, E.; Kawecki, A.; Rottey, S.; Erfan, J.; Zabolotnyy, D.; Kienzer, H.R.; Cupissol, D.; Peyrade, F.; Benasso, M.; Vynnychenko, I.; De Raucourt, D.; Bokemeyer, C.; Schueler, A.; Amellal, N.; Hitt, R. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med., 2008, 359, 1116-11127.
8. Vermorken, J.B.; Herbst, R.S.; Leon, X.; Amellal, N.; Baselga, J. Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies. Cancer, 2008, 112, 2710-2719.
9. Vissink, A.; Jansma, J.; Spijkervet, F.K.; Burlage, F.R.; Coppes, R.P. Oral sequelae of head and neck radiotherapy. Crit. Rev. Oral. Biol. Med., 2003, 14, 199-212.
10. Argiris, A.; Brockstein, B.E.; Haraf, D.J.; Stenson, K.M.; Mittal, B.B.; Kies, M.S.; Rosen, F.R.; Jovanovic, B.; Vokes, E.E. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin. Cancer. Res., 2004, 10, 1956-1962.
11. Jurenka, J.S. Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern. Med. Rev., 2009, 14, 141-153.
12. De, R.; Kundu, P.; Swarnakar, S.; Ramamurthy, T.; Chowdhury, A.; Nair, G.B.; Mukhopadhyay, A.K. Antimicrobial activity of curcumin against Helicobacter pylori isolates from India and during infections in mice. Antimicrob. Agents. Chemother., 2009, 53, 1592-1597.
13. Aftab, N.; Vieira, A. Antioxidant activities of curcumin and combinations of this curcuminoid with other phytochemicals. Phytother. Res., 2010, 24, 500-502.
14. Huang, M.T.; Lou, Y.R.; Xie, J.G.; Ma, W.; Lu, Y.P.; Yen, P.; Zhu, B.T.; Newmark, H.; Ho, C.T. Effect of dietary curcumin and dibenzoylmethane on formation of 7,12-dimethylbenz[a] anthracene-induced mammary tumors and lymphomas/leukemias in Sencar mice. Carcinogenesis, 1998, 19, 1697-1700.
15. Strofer, M.; Jelkmann, W.; Depping, R. Curcumin decreases survival of Hep3B liver and MCF-7 breast cancer cells: the role of HIF. Strahlenther. Onkol., 2011, 187, 393-400.
16. Hua, W.F.; Fu, Y.S.; Liao, Y.J.; Xia, W.J.; Chen, Y.C.; Zeng, Y.X.; Kung, H.F.; Xie, D. Curcumin induces down-regulation of EZH2 expression through the MAPK pathway in MDA-MB-435 human breast cancer cells. Eur. J. Pharmacol., 2010, 637, 16-21.
17. Kang, H.J.; Lee, S.H.; Price, J.E.; Kim, L.S. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB in breast cancer cells and potentiates the growth inhibitory effect of paclitaxel in a breast cancer nude mice model. Breast. J., 2009, 15, 223-229.
18. Narayan, S. Curcumin, a multi-functional chemopreventive agent, blocks growth of colon cancer cells by targeting beta-cateninmediated transactivation and cell-cell adhesion pathways. J. Mol. Histol., 2004, 35, 301-307.
19. Scott, D.W.; Loo, G. Curcumin-induced GADD153 gene upregulation in human colon cancer cells. Carcinogenesis, 2004, 25, 2155-2164.
20. Kim, K.C.; Lee, C. Curcumin Induces Downregulation of E2F4 Expression and Apoptotic Cell Death in HCT116 Human Colon Cancer Cells; Involvement of Reactive Oxygen Species. Korean. J. Physiol. Pharmacol., 2010, 14, 391-397.
21. Darvesh, A.S.; Aggarwal, B.B.; Bishayee, A. Curcumin and Liver Cancer: A Review. Curr. Pharm. Biotechnol., 2011.
22. Lin, H.P.; Kuo, L.K.; Chuu, C.P. Combined Treatment of Curcumin and Small Molecule Inhibitors Suppresses Proliferation of A549 and H1299 Human Non-Small-Cell Lung Cancer Cells. Phytother. Res., 2011.
23. Saha, A.; Kuzuhara, T.; Echigo, N.; Fujii, A.; Suganuma, M.; Fujiki, H. Apoptosis of human lung cancer cells by curcumin mediated through up-regulation of "growth arrest and DNA damage inducible genes 45 and 153". Biol. Pharm. Bull., 2010, 33, 1291-1299.
24. Wu, S.H.; Hang, L.W.; Yang, J.S.; Chen, H.Y.; Lin, H.Y.; Chiang, J.H.; Lu, C.C.; Yang, J.L.; Lai, T.Y.; Ko, Y.C.; Chung, J.G. Curcumin induces apoptosis in human non-small cell lung cancer NCI-H460 cells through ER stress and caspase cascade-and mitochondria-dependent pathways. Anticancer. Res., 2010, 30, 2125-2133.
25. Liu, S.; Wang, Z.; Hu, Z.; Zeng, X.; Li, Y.; Su, Y.; Zhang, C.; Ye, Z. Anti-tumor activity of curcumin against androgen-independent prostate cancer cells via inhibition of NF-kappaB and AP-1 pathway in vitro. J. Huazhong. Univ. Sci. Technolog. Med. Sci., 2011, 31, 530-534.
26. Choi, H.Y.; Lim, J.E.; Hong, J.H. Curcumin interrupts the interaction between the androgen receptor and Wnt/beta-catenin signaling pathway in LNCaP prostate cancer cells. Prostate. Cancer. Prostatic. Dis., 2010, 13, 343-349.
27. Yallapu, M.M.; Maher, D.M.; Sundram, V.; Bell, M.C.; Jaggi, M.; Chauhan, S.C. Curcumin induces chemo/radio-sensitization in ovarian cancer cells and curcumin nanoparticles inhibit ovarian cancer cell growth. J. Ovarian. Res., 2010, 3, 11.
28. Saydmohammed, M.; Joseph, D.; Syed, V. Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells. J. Cell. Biochem., 2010, 110, 447-456.
29. Li, Y.; Revalde, J.L.; Reid, G.; Paxton, J.W. Modulatory effects of curcumin on multi-drug resistance-associated protein 5 in pancreatic cancer cells. Cancer. Chemother. Pharmacol., 2011, 68, 603-610.
30. Epelbaum, R.; Schaffer, M.; Vizel, B.; Badmaev, V.; Bar-Sela, G. Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr. Cancer., 2010, 62, 1137-1141.
31. Gottschlich, S.; Ambrosch, P.; Cordes, C.; Gorogh, T.; Schreiber, S.; Hasler, R. Gene expression profiling of head and neck squamous cell carcinoma using cDNA microarrays. Int. J. Oncol., 2006, 29, 605-613.
32. Molinolo, A.A.; Amornphimoltham, P.; Squarize, C.H.; Castilho, R.M.; Patel, V.; Gutkind, J.S. Dysregulated molecular networks in head and neck carcinogenesis. Oral. Oncol., 2009, 45, 324-334.
33. Estilo, C.L.; O-charoenrat, P.; Talbot, S.; Socci, N.D.; Carlson, D.L.; Ghossein, R.; Williams, T.; Yonekawa, Y.; Ramanathan, Y.; Boyle, J.O.; Kraus, D.H.; Patel, S.; Shaha, A.R.; Wong, R.J.; Huryn, J.M.; Shah, J.P.; Singh, B. Oral tongue cancer gene expression profiling: Identification of novel potential prognosticators by oligonucleotide microarray analysis. BMC. Cancer., 2009, 9, 11.
34. Chang, K.W.; Hung, P.S.; Lin, I.Y.; Hou, C.P.; Chen, L.K.; Tsai, Y.M.; Lin, S.C. Curcumin upregulates insulin-like growth factor binding protein-5 (IGFBP-5) and C/EBPalpha during oral cancer suppression. Int. J. Cancer., 2010, 127, 9-20.
35. Shen, H.M.; Tergaonkar, V. NFkappaB signaling in carcinogenesis and as a potential molecular target for cancer therapy. Apoptosis, 2009, 14, 348-363.
36. Ondrey, F.G.; Dong, G.; Sunwoo, J.; Chen, Z.; Wolf, J.S.; Crowl-Bancroft, C.V.; Mukaida, N.; Van Waes, C. Constitutive activation of transcription factors NF-(kappa)B, AP-1, and NF-IL6 in human head and neck squamous cell carcinoma cell lines that express proinflammatory and pro-angiogenic cytokines. Mol. Carcinog., 1999, 26, 119-129.
37. Aggarwal, S.; Takada, Y.; Singh, S.; Myers, J.N.; Aggarwal, B.B. Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factorkappaB signaling. Int. J. Cancer., 2004, 111, 679-692.
38. Duarte, V.M.; Han, E.; Veena, M.S.; Salvado, A.; Suh, J.D.; Liang, L.J.; Faull, K.F.; Srivatsan, E. S.; Wang, M.B. Curcumin enhances the effect of cisplatin in suppression of head and neck squamous cell carcinoma via inhibition of IKKbeta protein of the NFkappaB pathway. Mol. Cancer. Ther., 2010, 9, 2665-2675.
39. LoTempio, M.M.; Veena, M.S.; Steele, H.L.; Ramamurthy, B.; Ramalingam, T.S.; Cohen, A.N.; Chakrabarti, R.; Srivatsan, E.S.; Wang, M.B. Curcumin suppresses growth of head and neck squamous cell carcinoma. Clin. Cancer. Res., 2005, 11, 6994-7002.
40. Wong, T.S.; Chan, W.S.; Li, C.H.; Liu, R.W.; Tang, W.W.; Tsao, S.W.; Tsang, R.K.; Ho, W.K.; Wei, W.I.; Chan, J.Y. Curcumin alters the migratory phenotype of nasopharyngeal carcinoma cells through up-regulation of E-cadherin. Anticancer. Res., 2010, 30, 2851-2856.
41. Lin, Y.T.; Wang, L.F.; Hsu, Y.C. Curcuminoids suppress the growth of pharynx and nasopharyngeal carcinoma cells through induced apoptosis. J. Agric. Food. Chem., 2009, 57, 3765-3770.
42. Shin, H.K.; Kim, J.; Lee, E.J.; Kim, S.H. Inhibitory effect of curcumin on motility of human oral squamous carcinoma YD-10B cells via suppression of ERK and NF-kappaB activations. Phytother. Res., 2010, 24, 577-582.
43. Ramji, D.P.; Foka, P. CCAAT/enhancer-binding proteins: structure, function and regulation. Biochem. J., 2002, 365, 561-575.
44. Bennett, K.L.; Hackanson, B.; Smith, L.T.; Morrison, C.D.; Lang, J.C.; Schuller, D.E.; Weber, F.; Eng, C.; Plass, C. Tumor suppressor activity of CCAAT/enhancer binding protein alpha is epigenetically down-regulated in head and neck squamous cell carcinoma. Cancer. Res., 2007, 67, 4657-4664.
45. Ji, C.; Chen, Y.; Centrella, M.; McCarthy, T.L. Activation of the insulin-like growth factor-binding protein-5 promoter in osteoblasts by cooperative E box, CCAAT enhancer-binding protein, and nuclear factor-1 deoxyribonucleic acid-binding sequences. Endocrinology, 1999, 140, 4564-4572.
46. Lin, S.C.; Wang, C.P.; Chen, Y.M.; Lu, S.Y.; Fann, M.J.; Liu, C.J.; Kao, S.Y.; Chang, K.W. Regulation of IGFBP-5 expression during tumourigenesis and differentiation of oral keratinocytes. J. Pathol., 2002, 198, 317-325.
47. Park, M.T.; Lee, S.J. Cell cycle and cancer. J. Biochem. Mol. Biol., 2003, 36, 60-65.
48. Malumbres, M.; Barbacid, M. Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer., 2009, 9, 153-166.
49. Kuo, C.L.; Wu, S.Y.; Ip, S.W.; Wu, P.P.; Yu, C.S.; Yang, J.S.; Chen, P.Y.; Wu, S.H.; Chung, J.G. Apoptotic death in curcumintreated NPC-TW 076 human nasopharyngeal carcinoma cells is mediated through the ROS, mitochondrial depolarization and caspase-3-dependent signaling responses. Int. J. Oncol., 2011, 39, 319-328.
50. Aggarwal, B.B.; Banerjee, S.; Bharadwaj, U.; Sung, B.; Shishodia, S.; Sethi, G. Curcumin induces the degradation of cyclin E expression through ubiquitin-dependent pathway and up-regulates cyclin-dependent kinase inhibitors p21 and p27 in multiple human tumor cell lines. Biochem. Pharmacol., 2007, 73, 1024-1032.
51. Burz, C.; Berindan-Neagoe, I.; Balacescu, O.; Irimie, A. Apoptosis in cancer: key molecular signaling pathways and therapy targets. Acta. Oncol., 2009, 48, 811-821.
52. Wang, D.; Veena, M.S.; Stevenson, K.; Tang, C.; Ho, B.; Suh, J.D.; Duarte, V.M.; Faull, K.F.; Mehta, K.; Srivatsan, E.S.; Wang, M.B. Liposome-encapsulated curcumin suppresses growth of head and neck squamous cell carcinoma in vitro and in xenografts through the inhibition of nuclear factor kappaB by an AKT-independent pathway. Clin. Cancer. Res., 2008, 14, 6228-6236.
53. Mitra, A.; Chakrabarti, J.; Banerji, A.; Chatterjee, A.; Das, B.R. Curcumin, a potential inhibitor of MMP-2 in human laryngeal squamous carcinoma cells HEp2. J. Environ. Pathol. Toxicol. Oncol., 2006, 25, 679-690.
54. Liao, S.; Xia, J.; Chen, Z.; Zhang, S.; Ahmad, A.; Miele, L.; Sarkar, F.H.; Wang, Z. Inhibitory effect of curcumin on oral carcinoma CAL-27 cells via suppression of Notch-1 and NF-kappaB signaling pathways. J. Cell. Biochem., 2011, 112, 1055-1065.
55. Manning, B.D.; Cantley, L.C. Rheb fills a GAP between TSC and TOR. Trends. Biochem. Sci., 2003, 28, 573-576.
56. Hay, N.; Sonenberg, N. Upstream and downstream of mTOR. Genes. Dev., 2004, 18, 1926-1945.
57. Molinolo, A.A.; Hewitt, S.M.; Amornphimoltham, P.; Keelawat, S.; Rangdaeng, S.; Meneses Garcia, A.; Raimondi, A.R.; Jufe, R.; Itoiz, M.; Gao, Y.; Saranath, D.; Kaleebi, G.S.; Yoo, G.H.; Leak, L.; Myers, E.M.; Shintani, S.; Wong, D.; Massey, H.D.; Yeudall, W.A.; Lonardo, F.; Ensley, J.; Gutkind, J.S. Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. Clin. Cancer. Res., 2007, 13, 4964-4973.
58. Massarelli, E.; Liu, D.D.; Lee, J.J.; El-Naggar, A.K.; Lo Muzio, L.; Staibano, S.; De Placido, S.; Myers, J.N.; Papadimitrakopoulou, V.A. Akt activation correlates with adverse outcome in tongue cancer. Cancer, 2005, 104, 2430-2436.
59. Yu, Z.; Weinberger, P.M.; Sasaki, C.; Egleston, B.L.; Speier, W.F.4th.; Haffty, B.; Kowalski, D.; Camp, R.; Rimm, D.; Vairaktaris, E.; Burtness, B.; Psyrri, A. Phosphorylation of Akt (Ser473) predicts poor clinical outcome in oropharyngeal squamous cell cancer. Cancer. Epidemiol. Biomarkers. Prev., 2007, 16, 553-558.
60. Clark, C.A.; McEachern, M.D.; Shah, S.H.; Rong, Y.; Rong, X.; Smelley, C.L.; Caldito, G.C.; Abreo, F.W.; Nathan, C.O. Curcumin inhibits carcinogen and nicotine-induced Mammalian target of rapamycin pathway activation in head and neck squamous cell carcinoma. Cancer. Prev. Res. (Phila), 2010, 3, 1586-1595.
61. Chakravarti, N.; Kadara, H.; Yoon, D.J.; Shay, J.W.; Myers, J.N.; Lotan, D.; Sonenberg, N.; Lotan, R. Differential inhibition of protein translation machinery by curcumin in normal, immortalized, and malignant oral epithelial cells. Cancer. Prev. Res. (Phila), 2010, 3, 331-338.
62. Darnell, J.E., Jr. Transcription factors as targets for cancer therapy. Nat. Rev. Cancer., 2002, 2, 740-749.
63. O'Shea, J.J.; Gadina, M.; Schreiber, R.D. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell, 2002, 109 Suppl, S121-131.
64. Reich, N.C.; Liu, L. Tracking STAT nuclear traffic. Nat. Rev. Immunol., 2006, 6, 602-612.
65. Grandis, J.R.; Drenning, S.D.; Chakraborty, A.; Zhou, M.Y.; Zeng, Q.; Pitt, A.S.; Tweardy, D.J. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth In vitro. J. Clin. Invest., 1998, 102, 1385-1392.
66. Sriuranpong, V.; Park, J.I.; Amornphimoltham, P.; Patel, V.; Nelkin, B.D.; Gutkind, J.S. Epidermal growth factor receptorindependent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system. Cancer. Res., 2003, 63, 2948-2956.
67. Chakravarti, N.; Myers, J.N.; Aggarwal, B.B. Targeting constitutive and interleukin-6-inducible signal transducers and activators of transcription 3 pathway in head and neck squamous cell carcinoma cells by curcumin (diferuloylmethane). Int. J. Cancer., 2006, 119, 1268-1275.
68. Zheng, Z.; Pan, J.; Chu, B.; Wong, Y.C.; Cheung, A.L.; Tsao, S.W. Downregulation and abnormal expression of E-cadherin and betacatenin in nasopharyngeal carcinoma: close association with advanced disease stage and lymph node metastasis. Hum. Pathol., 1999, 30, 458-466.
69. Chakraborti, S.; Mandal, M.; Das, S.; Mandal, A.; Chakraborti, T. Regulation of matrix metalloproteinases: an overview. Mol. Cell. Biochem., 2003, 253, 269-285.
70. Takahashi, H.; Shibuya, M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin. Sci. (Lond), 2005, 109, 227-241.
71. Dhillon, N.; Aggarwal, B.B.; Newman, R.A.; Wolff, R.A.; Kunnumakkara, A.B.; Abbruzzese, J.L.; Ng, C.S.; Badmaev, V.; Kurzrock, R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer. Res., 2008, 14, 4491-4499.
72. Carroll, R.E.; Benya, R.V.; Turgeon, D.K.; Vareed, S.; Neuman, M.; Rodriguez, L.; Kakarala, M.; Carpenter, P.M.; McLaren, C.; Meyskens, F.L., Jr.; Brenner, D.E. Phase IIa clinical trial of curcumin for the prevention of colorectal neoplasia. Cancer. Prev. Res. (Phila), 2011, 4, 354-364.
73. Bayet-Robert, M.; Kwiatkowski, F.; Leheurteur, M.; Gachon, F.; Planchat, E.; Abrial, C.; Mouret-Reynier, M.A.; Durando, X.; Barthomeuf, C.; Chollet, P. Phase I dose escalation trial of docetaxel plus curcumin in patients with advanced and metastatic breast cancer. Cancer. Biol. Ther., 2010, 9, 8-14.
74. Abuzeid, W.M.; Davis, S.; Tang, A.L.; Saunders, L.; Brenner, J.C.; Lin, J.; Fuchs, J.R.; Light, E.; Bradford, C.R.; Prince, M.E.; Carey, T.E. Sensitization of head and neck cancer to cisplatin through the use of a novel curcumin analog. Arch. Otolaryngol. Head. Neck. Surg., 2011, 137, 499-507.
75. Khafif, A.; Lev-Ari, S.; Vexler, A.; Barnea, I.; Starr, A.; Karaush, V.; Haif, S.; Ben-Yosef, R. Curcumin: a potential radio-enhancer in head and neck cancer. Laryngoscope, 2009, 119, 2019-2026.
76. Lopez-Jornet, P.; Camacho-Alonso, F.; Gomez-Garcia, F. Effect of curcumin and irradiation in PE/CA-PJ15 oral squamous cell carcinoma. Acta. Odontol. Scand., 2011, 69, 269-273.
77. Khafif, A.; Hurst, R.; Kyker, K.; Fliss, D.M.; Gil, Z.; Medina, J.E. Curcumin: a new radio-sensitizer of squamous cell carcinoma cells. Otolaryngol. Head. Neck. Surg., 2005, 132, 317-321.
78. Cheng, A.L.; Hsu, C.H.; Lin, J.K.; Hsu, M.M.; Ho, Y.F.; Shen, T.S.; Ko, J.Y.; Lin, J.T.; Lin, B.R.; Ming-Shiang, W.; Yu, H.S.; Jee, S.H.; Chen, G.S.; Chen, T.M.; Chen, C.A.; Lai, M.K.; Pu, Y.S.; Pan, M.H.; Wang, Y.J.; Tsai, C.C.; Hsieh, C.Y. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer. Res., 2001, 21, 2895-2900.
79. Sharma, R.A.; Euden, S.A.; Platton, S.L.; Cooke, D.N.; Shafayat, A.; Hewitt, H.R.; Marczylo, T.H.; Morgan, B.; Hemingway, D.; Plummer, S.M.; Pirmohamed, M.; Gescher, A.J.; Steward, W.P. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin. Cancer. Res., 2004, 10, 6847-6854.
80. Garcea, G.; Berry, D.P.; Jones, D.J.; Singh, R.; Dennison, A.R.; Farmer, P.B.; Sharma, R.A.; Steward, W.P.; Gescher, A.J. Consumption of the putative chemopreventive agent curcumin by cancer patients: assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer. Epidemiol. Biomarkers. Prev., 2005, 14, 120-125.
81. Anand, P.; Kunnumakkara, A.B.; Newman, R.A.; Aggarwal, B.B. Bioavailability of curcumin: problems and promises. Mol. Pharm., 2007, 4, 807-818.
82. Kim, S.G.; Veena, M.S.; Basak, S.K.; Han, E.; Tajima, T.; Gjertson, D.W.; Starr, J.; Eidelman, O.; Pollard, H.B.; Srivastava, M.; Srivatsan, E.S.; Wang, M.B. Curcumin treatment suppresses IKKbeta kinase activity of salivary cells of patients with head and neck cancer: a pilot study. Clin. Cancer. Res. 2011, 17, 5953-5961.
83. Liu, Z.; Xie, Z.; Jones, W.; Pavlovicz, R.E.; Liu, S.; Yu, J.; Li, P.K.; Lin, J.; Fuchs, J.R.; Marcucci, G.; Li, C.; Chan, K.K. Curcumin is a potent DNA hypomethylation agent. Bioorg. Med. Chem. Lett., 2009, 19, 706-709.
84. Bora-Tatar, G.; Dayangac-Erden, D.; Demir, A.S.; Dalkara, S.; Yelekci, K.; Erdem-Yurter, H. Molecular modifications on carboxylic acid derivatives as potent histone deacetylase inhibitors: Activity and docking studies. Bioorg. Med. Chem., 2009, 17, 5219-5228.
85. Liu, H.L.; Chen, Y.; Cui, G.H.; Zhou, J.F. Curcumin, a potent antitumor reagent, is a novel histone deacetylase inhibitor regulating BNHL cell line Raji proliferation. Acta. Pharmacol. Sin., 2005, 26, 603-609.
86. Marcu, M.G.; Jung, Y.J.; Lee, S.; Chung, E.J.; Lee, M.J.; Trepel, J.; Neckers, L. Curcumin is an inhibitor of p300 histone acetylatransferase. Med. Chem., 2006, 2, 169-174.
87. Morimoto, T.; Sunagawa, Y.; Kawamura, T.; Takaya, T.; Wada, H.; Nagasawa, A.; Komeda, M.; Fujita, M.; Shimatsu, A.; Kita, T.; Hasegawa, K. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J. Clin. Invest., 2008, 118, 868-878.
88. Sun, M.; Estrov, Z.; Ji, Y.; Coombes, K. R.; Harris, D. H.; Kurzrock, R. Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol. Cancer. Ther., 2008, 7, 464-473.
89. Saini, S.; Arora, S.; Majid, S.; Shahryari, V.; Chen, Y.; Deng, G.; Yamamura, S.; Ueno, K.; Dahiya, R. Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer. Cancer. Prev. Res. (Phila), 2011, 4, 1698-1709.
90. Zhang, J.; Zhang, T.; Ti, X.; Shi, J.; Wu, C.; Ren, X.; Yin, H. Curcumin promotes apoptosis in A549/DDP multidrug-resistant human lung adenocarcinoma cells through an miRNA signaling pathway. Biochem. Biophys. Res. Commun., 2010, 399, 1-6.
91. Mudduluru, G.; George-William, J.N.; Muppala, S.; Asangani, I.A.; Kumarswamy, R.; Nelson, L.D.; Allgayer, H. Curcumin regulates miR-21 expression and inhibits invasion and metastasis in colorectal cancer. Biosci. Rep., 2011, 31, 185-197.
92. Yang, J.; Cao, Y.; Sun, J.; Zhang, Y. Curcumin reduces the expression of Bcl-2 by upregulating miR-15a and miR-16 in MCF-7 cells. Med. Oncol., 2010, 27, 1114-1118.